Meyd-873 May 2026

By Dr. Alex Rivera, Ph.D. – Molecular Pharmacology & Drug Discovery
April 4 2026

Stay tuned as we move forward—MEYD‑873 could change the standard of care for KRAS‑driven solid tumors. MEYD-873

— Dr. Maya Patel, Head of Translational Oncology, NovaCure Therapeutics Stay tuned as we move forward— MEYD‑873 could

However, if we consider a general approach to writing about such a code, here are a few potential directions: Given the information you've provided, I can offer

Given the information you've provided, I can offer a very generic template for a write-up:

  • Log artifacts: Sudden gaps or redactions in metric ingestion logs between timestamps T1–T2.

    • (Replace placeholder hashes/IPs with exact values from forensic output before operational use.)

    | Question | Answer | |----------|--------| | Is MEYD‑873 a cure? | Not yet. It is a disease‑modifying therapy that aims to extend survival and improve quality of life. | | Who can enroll in the trial? | Adults (≥ 18 y) with confirmed KRAS‑G12D mutation and a RAF‑DimerScore ≥ 2, who have progressed after standard therapy. | | What are the most common side effects observed so far? | Mild nausea, transient fatigue, and occasional Grade 1–2 elevation of alkaline phosphatase—all manageable with standard supportive care. | | When will the drug be available? | If Phase 3 confirms efficacy, we anticipate a 2029 US launch (subject to regulatory approval). | | How does the companion diagnostic work? | A single‑plex NGS assay for KRAS‑G12D plus a validated IHC stain for RAF‑dimer activity; results are returned within 7 days. |